Kyverna outlines 2025 priorities; pivotal SPS trial 40% enrolled, BLA filing targeted for 2026

Kyverna Therapeutics, Inc.

40% enrolled in pivotal Phase 2 KYV-101 trial for stiff person syndrome; BLA filing targeted for 2026.
Cash runway into 2027 with $321.6M cash and securities as of Sep 30, 2024.
Myasthenia gravis: confirm registrational path 1H 2025, interim Phase 2 data 2H 2025.
Lupus nephritis: Phase 1 data expected 2H 2025; KYV-102 IND filing 2H 2025.
Company pivoting to late-stage development and commercialization with CD19 CAR T construct KYV-101.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.